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Introduction: In Victoria, Australia, cascade carrier testing is provided free of
charge to people with a family history of cystic ﬁbrosis (CF). Most children with CF
are diagnosed by newborn screening which includes DNA testing. The uptake of
cascade carrier testing following a child’s diagnosis by newborn screening has not
been previously described. The aim of this study is to report the uptake of cascade
carrier testing by Victorian families.
Method: Examination of pedigrees of children with CF born 2001–2004 revealed
the number of relatives eligible for cascade carrier testing. Relatives were eligible
if they were aged 18 years or above and the family mutation was known. Uptake
of cascade carrier testing was veriﬁed with the database of the DNA diagnostic
laboratory (the only Victorian laboratory providing CF carrier testing).
Results: The pedigrees of 53 children were examined. Cascade carrier testing
uptake was 16% (190/1160). Relationship to the child was associated with uptake;
parents represented the greatest proportion of tested individuals (81/190) followed
by aunts and uncles (47/190) and then grandparents (41/190). There was no
difference in the uptake of cascade carrier testing between the maternal relatives
and the paternal relatives. Four pedigrees indicated an existing family history of
CF.
Discussion: The majority of relatives of children with CF have not had cascade
carrier testing despite being at high risk. Investigation into barriers and facilitators
to cascade carrier testing is being conducted to explore factors associated with
uptake.
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Background: The R117H-associated phenotypes vary from classical CF to no
clinical disease and have made genetic counselling difﬁcult. Since implementation
of CF NBS, the observed high R117H frequency among neonates with elevated
IRT and two mutations has reinforced this issue.
Methods: Two retrospective studies were conducted: (1) a phenotypic study on 263
patients with two CFTR mutations including at least one R117H; (2) a retrospective
2002–2005 epidemiological study, aimed to determine the frequency of R117H and
other frequent mutations in about 6000 healthy individuals without family history
of CFTR pathology.
Results: (1) Among the 263 patients, including 92 neonates, detailed clinical
features were available for 247: severe classical CF, n = 2; isolated CBAVD, n = 60;
other CFTR-related disorders (CFTR-RD), n = 109; healthy, n = 76 (65 neonates,
reduced follow-up period); (2) Based on R117H and F508del allelic frequencies
in the general population of 0.25% and 1.0%, respectively, the [F508del]+[R117H]
genotype prevalence was evaluated at 1/20,000, the CFTR-RD penetrance at 4.2%
and the CF penetrance at 0.06%.
Conclusion: The very low penetrance of R117H with regard to classical CF leads
to consider R117H no longer as a CF-causing mutation and to reassure patients and
their families in view of genetic counselling.
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Objectives: The aim of this study was to detect CFTR mutations in genomic DNA
isolated from amniotic ﬂuid collected by amniocentesis at couples with previous
family history of cystic ﬁbrosis and to verify the absence of contamination with
maternal blood or cells by STR genotyping, in order to provide a correct genetic
counseling.
Method and Materials: Based on family history or typical echographic ﬁndings, 8
couples were selected for prenatal diagnosis. Genomic DNA was isolated from
amniotic ﬂuid collected by transabdominal amniocentesis in the 16th week of
pregnancy and maternal venous blood collected on EDTA. The genetic analysis for
CFTR mutations was performed with Elucigene CF29 kit which uses the ARMS-
PCR method. We performed STR genotyping for several loci by polyacrilamide gel
electrophoresis in order to verify the absence of contamination with maternal blood
or cells of the amniotic ﬂuid.
Results: we identiﬁed 3 heterozygous genotypes (DF508/N, G542X/N), four normal
genotypes and one compound heterozygote (621+1G>T/DF508). The STR geno-
typing results showed the absence of contamination with maternal DNA of fetal
DNA.
Conclusions: Prenatal diagnosis can be performed by ARMS-PCR using Elucigene
CF29 kit only in cases were the detected genotype has at least one allele with DF508
mutation or is a compound heterozygote for the other mutations detected by the kit.
STR genotyping is a good complementary method which can be used for obtaining
a correct prenatal diagnosis.
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Hyperechogenic fetal bowel (HFB) is detected in 0.1−1.8% of pregnancies during
the second or third trimester, and could constitutes a prenatal sign of CF. It has
been reported that the prevalence of meconium ileus (MI), an early manifestation
of CF, is higher among neonates with previous HFB than in neonates with normal
ultrasound imaging. There could be a relationship between HFB and MI.
The aims were to evaluate usefulness and limits of genetic analysis in couples with
HFB, and to deﬁne the best testing strategy based on a review of CF patients with
MI.
Results of genetic analysis on 79 Italian CF patients with MI, and 47 HFB couples
were reviewed.
Screening for the most frequent mutations in 79 MI patients allowed a 90.5%
detection rate, which increased to 96.8% after DNA sequencing, and to 98.1%
after MLPA; two couples of carriers were identiﬁed, and in both prenatal diagnosis
conﬁrmed CF in the fetus. A third couple, whose child carried F508del and P5L,
chose to terminate the pregnancy. In a further pregnancy the fetus again had HFB,
and prenatal diagnosis showed heterozygosity for F508del. Because of the severity
of the ultrasound picture, this pregnancy was terminated.
Testing the most frequent mutations and deletions covers 91.8% of CFTR mutations
in CF with MI. A similar testing strategy may be appropriate in HFB. We do not
suggest to sequence the gene, because of the possibility of identifying mutations
with unknown/unclear clinical consequences. We also suggest to proceed with
extreme caution when counselling parents of a fetus with HFB who are carriers of
mild or novel mutations, as their presence in the fetus does not justify a diagnosis
of CF.
